Aveo, Delcath FDA Panel Live Blog

BOSTON ( TheStreet) -- Welcome to the doubleheader FDA advisory panel live blog: The morning panel features Aveo Oncology ( AVEO) and its kidney cancer drug tivozanib. In the afternoon session, Delcath Systems ( DCTH) brings the Melblez liver-tumor therapy in front of the FDA's outside experts.

The panel experts will consider the efficacy and safety of tivozanib and Melblez and vote to recommend approval -- or not. The final approval decision rests with the FDA.

Expect trading in both Aveo and Delcath to be halted during their respective panel sessions. Both stocks have been under pressure this week on FDA reviews which raised concerns and questions about the clinical benefit and/or safety of tivozanib and Melblez. It will be the job of Aveo and Delcath to counter these concerns and convince the panel members that their respective products deserve FDA approval.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Biotech Names Flexing Their Muscles

Biotech Names Flexing Their Muscles

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

How I'm Prepared for Irma -- and a Pullback

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge